|
US5686465A
(en)
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5395842A
(en)
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
US5254568A
(en)
|
1990-08-09 |
1993-10-19 |
Council Of Scientific & Industrial Research |
Benzopyrans as antiestrogenic agents
|
|
EP0470310B1
(en)
|
1990-08-09 |
1995-11-29 |
Council of Scientific and Industrial Research |
Novel benzopyrans and process for their production
|
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
ES2105525T3
(es)
|
1993-06-24 |
1997-10-16 |
Lilly Co Eli |
2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
|
|
US5446061A
(en)
|
1993-11-05 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5407947A
(en)
*
|
1993-11-05 |
1995-04-18 |
Eli Lilly And Company |
Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
|
|
US5416098A
(en)
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
|
US5389646A
(en)
|
1993-12-30 |
1995-02-14 |
Zymogenetics, Inc. |
Methods for treatment and prevention of bone loss using 2,3-benzopyrans
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
TW398975B
(en)
|
1994-07-22 |
2000-07-21 |
Lilly Co Eli |
Pharmaceutical composition for inhibiting bone loss
|
|
US5637598A
(en)
|
1994-11-18 |
1997-06-10 |
Eli Lilly And Company |
Methods of inhibiting bone loss
|
|
US5446071A
(en)
|
1994-11-18 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5980938A
(en)
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
JP2001502708A
(ja)
*
|
1996-10-28 |
2001-02-27 |
ノボ ノルディスク アクティーゼルスカブ |
エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体
|
|
WO1999002512A1
(en)
|
1997-07-09 |
1999-01-21 |
Novo Nordisk A/S |
Dl-2,3-diaryl-2h-1-benzopyrans
|
|
WO1999002513A1
(en)
|
1997-07-09 |
1999-01-21 |
Novo Nordisk A/S |
Preparation of diaryl-benzopyrans
|
|
HUP0002852A3
(en)
|
1997-08-15 |
2001-11-28 |
Univ Durham |
A method of preventing or treating estrogen-dependent diseases and disorders using triphenil-ethylene derivatives
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
UA68365C2
(en)
|
1997-11-06 |
2004-08-16 |
Wyeth Corp |
Peroral contraception by combination of anti-estrogen and progestin
|
|
JP2002516983A
(ja)
|
1998-03-30 |
2002-06-11 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
核受容体活性を調節するための方法及び化合物
|
|
WO1999060014A2
(en)
|
1998-03-30 |
1999-11-25 |
The Regents Of The University Of California |
Methods and compounds for modulating nuclear receptor coactivator binding
|
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US7005428B1
(en)
|
1998-06-11 |
2006-02-28 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
ES2188222T3
(es)
|
1998-08-14 |
2003-06-16 |
Schering Corp |
Sintesis enantioselectiva.
|
|
US6262270B1
(en)
*
|
1998-08-14 |
2001-07-17 |
Schering Corporation |
Enantioselective synthesis
|
|
AU2156800A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Oral antiestrogen pharmaceutical composition
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
DE19916419B4
(de)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
|
|
DE60043305D1
(de)
|
1999-07-06 |
2009-12-24 |
Endorech Inc |
Pharmazeutische zubereitungen zur behandlung von insulinresitenz
|
|
AU7896100A
(en)
|
1999-10-14 |
2001-04-23 |
Endorecherche Inc. |
Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
RU2342145C2
(ru)
|
2000-01-28 |
2008-12-27 |
Андорешерш, Инк. |
Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
|
|
AU2001238700A1
(en)
|
2000-02-22 |
2001-09-03 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of het, a novel modulator of estrogen action
|
|
DE10013782A1
(de)
*
|
2000-03-15 |
2001-10-18 |
Schering Ag |
4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6528681B2
(en)
|
2000-04-05 |
2003-03-04 |
Bristol-Meyers Squibb Pharma Company |
Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US8119138B2
(en)
|
2000-05-10 |
2012-02-21 |
Signe Biopharma Inc. |
Anti-estrogen and immune modulator combinations for treating breast cancer
|
|
US7863011B2
(en)
|
2000-05-10 |
2011-01-04 |
Signe Biopharma, Inc. |
Screening method for predicting susceptibility to breast cancer
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
ES2228932T3
(es)
|
2000-08-11 |
2005-04-16 |
Wyeth |
Procedimiento de tratamiento del carcinoma positivo de estrogenos.
|
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
|
EP1317270A1
(en)
|
2000-09-08 |
2003-06-11 |
Pharmacia Italia S.p.A. |
Exemestane for the treatment of oestrogen-dependent cancers
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
CA2424299A1
(en)
|
2000-10-06 |
2002-04-18 |
Biomedicines, Inc. |
Combination therapy for the treatment of estrogen-sensitive disease
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
CA2424729A1
(en)
|
2000-10-19 |
2002-04-25 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2002032373A2
(en)
|
2000-10-19 |
2002-04-25 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
US20040082557A1
(en)
|
2001-01-26 |
2004-04-29 |
Wajszczuk Charles Paul |
Methods for treating estrogen-dependent disorders
|
|
CA2434611A1
(en)
|
2001-01-26 |
2002-09-19 |
Pharmacia Italia Spa |
Combined method for treating hormono-dependent disorders
|
|
GB2374412A
(en)
|
2001-04-11 |
2002-10-16 |
Karobio Ab |
Hypertension treatment and assay
|
|
CZ2004220A3
(cs)
|
2001-08-11 |
2004-06-16 |
Bristol-Myers Squibb Pharma Company |
Název neuveden
|
|
US20040235808A1
(en)
|
2001-09-21 |
2004-11-25 |
Jiabing Wang |
Androstanes as androgen receptor modulators
|
|
US7402577B2
(en)
|
2001-10-03 |
2008-07-22 |
Merck & Co., Inc. |
Androstane 17-beta-carboxamides as androgen receptor modulators
|
|
EP1435967A2
(en)
|
2001-10-10 |
2004-07-14 |
Pharmacia Italia S.p.A. |
Methods for preventing and treating bone loss with steroid compounds
|
|
CA2463311A1
(en)
|
2001-10-19 |
2003-05-01 |
Paul J. Coleman |
Androgen receptor modulators and methods of use thereof
|
|
ATE321764T1
(de)
*
|
2001-12-19 |
2006-04-15 |
Ortho Mcneil Pharm Inc |
Tetracyclische heteroverbindungen als modulatoren des östrogenrezeptors
|
|
US7105679B2
(en)
*
|
2001-12-19 |
2006-09-12 |
Kanojia Ramesh M |
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
|
|
EP1465619A1
(en)
|
2002-01-14 |
2004-10-13 |
Nordic Bioscience A/S |
Suppression of cartilage degradation via the estrogen receptor
|
|
WO2003070253A1
(en)
|
2002-02-21 |
2003-08-28 |
Pantarhei Bioscience B.V. |
Estrogenic component for treating decreased libido in women
|
|
EP1483401A1
(en)
|
2002-03-13 |
2004-12-08 |
F.Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
KR100938136B1
(ko)
|
2002-03-13 |
2010-01-22 |
머크 앤드 캄파니 인코포레이티드 |
안드로겐 수용체 조정자로서의 불화된 4-아자스테로이드 유도체 및 이를 포함하는 약제학적 조성물
|
|
US20030225132A1
(en)
|
2002-04-11 |
2003-12-04 |
Dininno Frank P. |
Estrogen receptor modulators
|
|
SI1501819T1
(sl)
|
2002-04-24 |
2011-01-31 |
Merck Sharp & Dohme |
Modulatorji estrogen receptorjev
|
|
WO2003092588A2
(en)
|
2002-04-30 |
2003-11-13 |
Merck & Co., Inc. |
4-azasteroid derivatives as androgen receptor modulators
|
|
CN1662241A
(zh)
|
2002-06-25 |
2005-08-31 |
惠氏公司 |
环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途
|
|
TW200407124A
(en)
|
2002-06-25 |
2004-05-16 |
Wyeth Corp |
Use of thio-oxindole derivatives in treatment of hormone-related conditions
|
|
JP2006513159A
(ja)
|
2002-11-01 |
2006-04-20 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
|
|
WO2004091488A2
(en)
|
2003-04-14 |
2004-10-28 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
JP4832303B2
(ja)
|
2003-05-07 |
2011-12-07 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体モジュレータおよびこれらの使用
|
|
SI1622630T1
(sl)
|
2003-05-07 |
2012-12-31 |
Osteologix A/S |
Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
EP1641535A4
(en)
|
2003-06-30 |
2008-05-14 |
Merck & Co Inc |
17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
|
|
WO2005005606A2
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
AU2004259664B2
(en)
|
2003-06-30 |
2009-05-28 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
CA2530048A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
AU2004272004B2
(en)
|
2003-09-10 |
2009-01-22 |
Merck Sharp & Dohme Corp. |
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
CN1849120A
(zh)
|
2003-09-10 |
2006-10-18 |
默克公司 |
作为雄激素受体调节剂的17－杂环－4－氮杂甾类衍生物
|
|
DE602004014806D1
(de)
|
2003-10-08 |
2008-08-14 |
Smithkline Beecham Corp |
Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
|
|
CN1871005B
(zh)
|
2003-10-31 |
2010-10-27 |
默沙东公司 |
雄激素受体调节剂21-杂环-4-氮杂甾体衍生物
|
|
WO2005073190A1
(en)
|
2004-01-29 |
2005-08-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
WO2005123130A2
(en)
|
2004-06-17 |
2005-12-29 |
Osteologix A/S |
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
|
|
JP2008502609A
(ja)
|
2004-06-17 |
2008-01-31 |
オステオロジックス エイ／エス |
リウマチおよび関節性疾患の治療改善方法
|
|
KR20070059110A
(ko)
|
2004-09-03 |
2007-06-11 |
호르모스 메디칼 리미티드 |
안드로겐 결핍의 치료 또는 예방에 사용하는 제제의 제조를위한 선택적 에스트로겐 수용체 조절자의 용도
|
|
CN102357248A
(zh)
|
2004-10-20 |
2012-02-22 |
恩多研究公司 |
单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
|
|
WO2006084937A1
(en)
|
2005-02-14 |
2006-08-17 |
Leskelae Hannu-Ville |
Method for diagnosing and treating women with increased response to hormonal replacement therapy
|
|
US20070078114A1
(en)
|
2005-09-02 |
2007-04-05 |
Myriad Genetics, Incorporated |
Combination therapy for alzheimer's disease and other diseases
|
|
WO2007098090A2
(en)
|
2006-02-17 |
2007-08-30 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
|
|
US20080268041A1
(en)
|
2007-04-23 |
2008-10-30 |
Jens Hoffmann |
Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
|
|
DE102007026877A1
(de)
|
2007-06-08 |
2008-12-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
|
|
US20110104121A1
(en)
|
2008-05-21 |
2011-05-05 |
Wira Charles R |
Female Reproductive Tract and Anal Prophylaxes
|
|
WO2010107474A1
(en)
|
2009-03-16 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Antiestrogens for breast cancer therapy
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
HUE033581T2
(hu)
*
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US9540361B2
(en)
|
2010-12-24 |
2017-01-10 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
SG11201403002RA
(en)
|
2011-12-14 |
2014-07-30 |
Seragon Pharmaceuticals Inc |
Fluorinated estrogen receptor modulators and uses thereof
|
|
EP2791128A4
(en)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
|